Oncopeptides Logo

Oncopeptides

Develops targeted therapies for hematological cancers using peptide-drug conjugate technology.

ONCO | ST

Overview

Corporate Details

ISIN(s):
SE0009414576 (+4 more)
LEI:
549300J9WWQ5CBYQ1M77
Country:
Sweden
Address:
Luntmakargatan 46, 111 37 Stockholm
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Oncopeptides AB is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers, particularly hematological diseases. Founded in 2000, the company leverages its proprietary Peptide Drug Conjugate technology platforms to develop innovative treatments. Its lead product, Pepaxti® (melflufen), is a treatment for adult patients with relapsed refractory multiple myeloma (RRMM). Oncopeptides is actively commercializing Pepaxti in Europe and conducts real-world evidence studies to support the drug's effectiveness and tolerability in clinical practice. The company's mission is to address significant unmet medical needs and provide hope to cancer patients through scientific innovation.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-21 08:30
Regulatory News Service
Oncopeptides har utsett valberedningen
Swedish 63.1 KB
2025-11-21 08:30
Regulatory News Service
Oncopeptides announces the Nomination Committee
English 62.7 KB
2025-11-05 08:00
Quarterly Report
Swedish 550.9 KB
2025-11-05 08:00
Quarterly Report
English 636.0 KB
2025-10-31 08:30
Declaration of Voting Results & Voting Rights Announcements
Antal aktier och röster i Oncopeptides
Swedish 68.1 KB
2025-10-31 08:30
Declaration of Voting Results & Voting Rights Announcements
Number of shares and votes in Oncopeptides
English 67.6 KB
2025-10-28 09:37
Major Shareholding Notification
Swedish 10.4 KB
2025-10-13 18:45
Capital/Financing Update
Oncopeptides issues warrants to fulfil its obligations under loan agreement wit…
English 76.0 KB
2025-10-13 18:45
Capital/Financing Update
Oncopeptides emitterar teckningsoptioner för att uppfylla sina skyldigheter und…
Swedish 76.7 KB
2025-10-10 13:36
Major Shareholding Notification
Swedish 10.8 KB
2025-10-08 09:50
Major Shareholding Notification
Swedish 10.5 KB
2025-09-30 10:00
Declaration of Voting Results & Voting Rights Announcements
Antal aktier och röster i Oncopeptides
Swedish 68.1 KB
2025-09-30 10:00
Declaration of Voting Results & Voting Rights Announcements
Number of shares and votes in Oncopeptides
English 67.7 KB
2025-09-17 08:30
Share Issue/Capital Change
Oncopeptides’ rights issue oversubscribed to approximately 157 percent
English 86.0 KB
2025-09-17 08:30
Share Issue/Capital Change
Oncopeptides företrädesemission övertecknad till cirka 157 procent
Swedish 86.2 KB

Automate Your Workflow. Get a real-time feed of all Oncopeptides filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Oncopeptides

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Oncopeptides via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-04-15 David Augustsson Other Buy 1,250 6,350.00 SEK
2024-04-15 David Augustsson Other Buy 1,250 6,312.50 SEK
2024-04-15 David Augustsson Other Buy 438 2,225.04 SEK
2024-04-15 David Augustsson Other Buy 60 303.60 SEK
2024-04-15 David Augustsson Other Buy 2 10.02 SEK
2023-09-08 David Augustsson Other Buy 2,296 17,706.75 SEK
2023-08-10 David Augustsson Other Buy 1,704 14,995.20 SEK
2023-05-04 Nicolaas Bakker Other Buy 5,000 42,380.00 SEK
2022-10-10 Nicolaas Bakker Other Buy 15,000 164,400.00 SEK
2022-08-30 Per Wold-Olsen Other Buy 2,050 55,350.00 SEK

Peer Companies

Assertio Holdings, Inc. Logo
Offers branded prescription drugs for neurology, pain, and CNS to US patients.
United States of America
ASRT
Astellas Pharma Inc. Logo
A global pharmaceutical company developing innovative medicines for unmet needs, focusing on oncology.
Japan
4503
Astena Holdings Co., Ltd. Logo
Develops and sells chemicals, pharma, and ingredients for food, cosmetic, and industrial use.
Japan
8095
AstraZeneca PLC Logo
Global biopharma developing medicines for oncology, cardiovascular, respiratory & rare diseases.
United Kingdom
AZN
Astria Therapeutics, Inc. Logo
Developing long-acting therapies for rare allergic and immunologic diseases like HAE.
United States of America
ATXS
ATAI Life Sciences N.V. Logo
Clinical-stage biopharma creating novel psychedelic drugs for mental health disorders.
United States of America
ATAI
Atara Biotherapeutics, Inc. Logo
Pioneering off-the-shelf allogeneic T-cell immunotherapies for cancer and autoimmune diseases.
United States of America
ATRA
Atea Pharmaceuticals, Inc. Logo
A clinical-stage biopharma developing oral antiviral therapies for viruses like Hepatitis C.
United States of America
AVIR
Athira Pharma, Inc. Logo
Developing small-molecule therapies to slow neurodegeneration in diseases like Alzheimer's.
United States of America
ATHA
ATOSSA THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing (Z)-endoxifen for breast cancer treatment and prevention.
United States of America
ATOS

Talk to a Data Expert

Have a question? We'll get back to you promptly.